Sanofi: Triggering Regenerative Functions
February 2010. What requirements stem cell technologies have to fulfil? What is the relationship to biomarker development? Which types of stem cells are most promising in order to meet Sanofi-Aventis’ strategic development goals? What combination with small molecules? Which complementary technologies are needed? Kurt Stoeckli, at the time Global Head of Biological Sciences / Discovery Sanofi Aventis and Scientific Director of the research site at Vitry-Alfortville (FR).
Includes Sanofi Aventis’ early - / late-stage pipelines Pharma & Vaccines 2010Reading time: 9 min
Read Now: |
Other articles recommended
B2Bioworld offers you background information
Stem Cells and Vaccines in Biomanufacturing
Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan K. C. Knowles, at the time Head of Roche Group Research - open access
Thinking Further About Stem Cells - Viewed from Systems Biology
Leroy Hood, President Institute for Systems Biology, Seattle, Washington (US)
Bayer AG: New stakes in stem cells
Andreas Busch, Head of Global Drug Discovery on results, technology platforms, and expectations
Stem Cell Research Now and in the Future - Viewed from GSK
Sir Patrick Vallance, at the time President Pharmaceuticals, R&D of GlaxoSmithKline
Novo Nordisk - Commercialising Stem Cells
“Doing our business a little bit differently …”